(Q34551039)

3 August 2017

title

Colitis in patients with breast carcinoma treated with taxane-based chemotherapy (English)

1 reference

3 August 2017

1 reference

1 reference

1 reference

9

Gabriel N Hortobagyi

1 reference

3 August 2017

8

Aman U Buzdar

1 reference

3 August 2017

Zhiyong Li

1

1 reference

3 August 2017

Nuhad K Ibrahim

2

1 reference

3 August 2017

Jay K Wathen

3

1 reference

3 August 2017

Michael Wang

4

1 reference

3 August 2017

Rosario P Mante Menchu

5

1 reference

3 August 2017

Vicente Valero

6

1 reference

3 August 2017

Richard Theriault

7

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

3 August 2017

1 reference

3 August 2017

volume

101

1 reference

3 August 2017

issue

7

1 reference

3 August 2017

page(s)

1508-1513

1 reference

Necrotizing colitis in patients with cancer

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Recurrent typhlitis. A disease resulting from aggressive chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

The taxanes: an update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Typhlitis. An 18-year experience and postmortem review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Intestinal perforation secondary to paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

A retrospective review of paclitaxel-associated gastrointestinal necrosis in patients with epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Typhlitis associated with docetaxel treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Taxol: a novel investigational antimicrotubule agent

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20546

7 January 2021

Identifiers

DOI

10.1002/CNCR.20546

1 reference

3 August 2017

1 reference